Your browser doesn't support javascript.
loading
Relationship of Soluble Lectin-Like Low-Density Lipoprotein Receptor-1 (sLOX-1) With Inflammation and Coronary Plaque Progression in Psoriasis.
Florida, Elizabeth M; Li, Haiou; Hong, Christin G; Ongstad, Emily L; Gaddipati, Ranjitha; Sitaula, Sadichha; Varma, Vijayalakshmi; Parel, Philip M; O'Hagan, Ross; Chen, Marcus Y; Teague, Heather L; Playford, Martin P; Karathanasis, Sotirios K; Collén, Anna; Mehta, Nehal N; Remaley, Alan T; Sorokin, Alexander V.
Afiliación
  • Florida EM; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Li H; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Hong CG; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Ongstad EL; Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD USA.
  • Gaddipati R; Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD USA.
  • Sitaula S; Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD USA.
  • Varma V; Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD USA.
  • Parel PM; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • O'Hagan R; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Chen MY; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Teague HL; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Playford MP; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Karathanasis SK; NeoProgen Baltimore MD USA.
  • Collén A; Section of Lipoprotein Metabolism, Translational Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Mehta NN; Projects, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD USA.
  • Remaley AT; Section of Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda MD USA.
  • Sorokin AV; Section of Lipoprotein Metabolism, Translational Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health Bethesda MD USA.
J Am Heart Assoc ; : e031227, 2023 Nov 20.
Article en En | MEDLINE | ID: mdl-37982276
BACKGROUND: Psoriasis is a chronic inflammatory condition associated with coronary artery disease risk. Uptake of oxidized low-density lipoprotein by the lectin-like low-density lipoprotein receptor-1 triggers release of the soluble extracellular domain of the receptor (sLOX-1). We sought to characterize the relationship between sLOX-1, inflammation, and coronary plaque progression in psoriasis. METHODS AND RESULTS: A total of 327 patients with psoriasis had serum sLOX-1 levels measured at baseline by an ELISA-based assay. Stratification by high-sensitivity C-reactive protein ≥4.0 mg/L (quartile 4), identified 81 participants who had coronary plaque phenotyping at baseline and were followed longitudinally by coronary computed tomography angiography. Subjects within high-sensitivity C-reactive protein quartile 4 were middle-aged (51.47±12.62 years), predominantly men (54.3%) with moderate psoriasis disease severity (6.60 [interquartile range, 3.30-13.40]). In the study cohort, participants with sLOX-1 above the median displayed increased vulnerable coronary plaque features. At baseline, sLOX-1 was associated with total burden (rho=0.296; P=0.01), noncalcified burden (rho=0.286; P=0.02), fibro-fatty burden (rho=0.346; P=0.004), and necrotic burden (rho=0.394; P=0.002). A strong relationship between sLOX-1, noncalcified burden (ß=0.19; P=0.03), and fibro-fatty burden (ß=0.29; P=0.003) was found in fully adjusted models at baseline and 1- and 4-year follow-up. Finally, coronary plaque features progressed over 1 year regardless of biologic or systemic treatment in subjects with high sLOX-1. CONCLUSIONS: Patients with psoriasis with both high sLOX-1 and high-sensitivity C-reactive protein levels have increased coronary plaque burden associated with atherosclerotic plaque progression independent of biologic and systemic treatment. Thus, sLOX-1 might be considered as a promising marker in coronary artery disease risk estimation beyond traditional risk factors. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01778569.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Am Heart Assoc Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Am Heart Assoc Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido